Pharmacoeconomic evaluation of treating acute venous thromboembolism with rivaroxaban in the inpatient setting

Abstract

Cost reduction associated with the use of rivaroxaban compared with the enoxaparin + warfarin combination for for deep vein thrombosis and pulmonary thromboembolism when treated in the inpatient setting. The choice of the cost reduction method is conditioned by the evidence from the randomized controlled studies EINSTEIN DVT and EINSTEIN PE, stating that rivaroxaban is no less effective compared with enoxaparin in combination with warfarin. The difference in the cost of the drugs is calculated from the healthcare perspective taking into account the risk of major bleeding. The price values were sourced from public procurement tenders (zakupki.gov.ru) in quarters I-IV 2013 and quarter I 2014. Costs associated with the treatment of major bleeding were defined on the basis of the obligatory medical insurance rates for Moscow in 2013. The authors demonstrated that use of rivaroxaban compared with enoxaparin and warfarin results in cost savings for the medicinal treatment of DVT and PTE in the amount of 2,020.71 and 3,353.35 rubles per patient, respectively. The revealed pattern is resistant to real-life fluctuations in prices for medicines.

Keywords

• анализ минимизации затрат
• тромбоз глубоких вен (тгв)
• тромбоэмболия легочных артерий (тэла)
• ривароксабан
• эноксапарин
• варфарин
• cost reduction evaluation
• deep vein thrombosis (dvt)
• pulmonary thromboembolism (pte)
• rivaroxaban
• enoxaparin
• warfarin